Article

News

Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine

Author(s):

Glaucoma specialist Joel Solano, MD, connects patients diagnosed with glaucoma with digital health solutions that can help prevent blindness and vision loss.

Eyecbetter hopes to raise funds to further develop and market its digital health solutions, which include a wearable, no-touch, no-airpuff home tonometer and a patient app that provides real-time health nudges and seamless connectivity to glaucoma healthcare providers between clinic appointments. (Image courtesy of Adobe Stock)

Eyecbetter hopes to raise funds to further develop and market its digital health solutions, which include a wearable, no-touch, no-airpuff home tonometer and a patient app that provides real-time health nudges and seamless connectivity to glaucoma healthcare providers between clinic appointments. (Image courtesy of Adobe Stock)

Eyecbetter, a glaucoma digital health company founded by Joel Solano, MD, is excited to announce the launch of its Regulation C Crowdfunding Campaign on StartEngine.

According to a news release, eyecbetter hopes to raise funds to further develop and market its digital health solutions, which include a wearable, no-touch, no-airpuff home tonometer and a patient app that provides real-time health nudges (with human care coordinator coaching) and seamless connectivity to glaucoma healthcare providers between clinic appointments.

Glaucoma, one of the leading causes of irreversible blindness worldwide, affects more than 100 million people globally. Driven by a passion to make a difference, Solano founded eyecbetter with the vision to improve the outcomes and quality of life for glaucoma patients.

According to the company, it has developed a suite of digital health solutions that empower patients to proactively monitor and manage their glaucoma from the comfort of their homes. Eyecbetter's Mobile App leverages artificial intelligence and machine learning algorithms to deliver accurate and personalized glaucoma monitoring and lifestyle recommendations.

The company noted in its news release its near-term goals include accelerating our research and development efforts, streamlining regulatory approvals, and expanding our marketing reach. This campaign presents a unique opportunity for investors passionate about transforming glaucoma care and enhancing patient outcomes to support the groundbreaking work of Solano and his team.

"I am thrilled to launch our Regulation C Crowdfunding Campaign on StartEngine and invite everyone to join us on this transformative journey to revolutionize glaucoma care," Solano said in a news release. "Eyecbetter's innovative digital health solutions empower patients to actively engage in the management of their eye disease, leading to better outcomes and an improved quality of life. With the support of our investors, we can create a significant impact on the lives of millions living with glaucoma."

According to the news release, StartEngine is a leading equity crowdfunding platform that connects groundbreaking startups with investors seeking innovative opportunities. With StartEngine and its team, eyecbetter is raising funds while also providing an opportunity for individuals to become part of the glaucoma digital health revolution.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
© 2025 MJH Life Sciences

All rights reserved.